Crohn’s Disease Therapeutics Industry Size, Share & Growth Forecast 2033

Crohn’s Disease Therapeutics by Type (/> Non-Surgical, Surgical), by Application (/> Hospitals, Ambulatory Surgical Centers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $7500 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $7500 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Crohn’s Disease Therapeutics Market Overview

Crohn’s Disease Therapeutics encompass biologics, small‑molecule oral agents, and biosimilars designed to modulate immune pathways and alleviate chronic gastrointestinal inflammation. The Crohn’s Disease Therapeutics market size is estimated at $15.1 billion in 2025, with a market forecast projecting $22.3 billion by 2033, translating to a CAGR of approximately 5.2% for the 2026‑2033 horizon. The growth outlook is propelled by rising global prevalence, accelerated biologic pipeline approvals, expanding biosimilar adoption, and heightened reimbursement support in mature markets. Key forces shaping the industry include the shift toward oral small‑molecule therapies, intensified competition from biosimilars eroding biologic pricing, and evolving regulatory frameworks that streamline accelerated approvals. North America remains the largest market, while Asia‑Pacific is emerging as the fastest‑growing region driven by increasing diagnosis rates and expanding healthcare infrastructure.

Loading chart…

Strategically, incumbents are leveraging next‑generation biologics and combination regimens to sustain premium positioning, while newcomers exploit cost‑advantageous biosimilars to capture market share. Consumer behavior—particularly patient preference for oral administration—accelerates diversification of the therapeutic portfolio. Supply‑chain resilience, especially in biologic manufacturing, remains a focal point as demand intensifies across emerging markets. Executives should prioritize pipeline investments in targeted small‑molecule agents, forge strategic alliances for biosimilar distribution, and monitor regulatory shifts that could reshape reimbursement landscapes, ensuring robust participation in the anticipated industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	7.50 billion
Revenue forecast in 2033	14.09 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson and Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; UCB India Private Limited.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Crohn’s Disease Therapeutics market is being reshaped by shifting clinical paradigms, regulatory incentives, and evolving payer models, creating a dynamic environment that demands strategic foresight from executives overseeing portfolio growth and risk mitigation.

Growth Drivers2 items

Expansion of biologics pipelines and accelerated biosimilar approvals—spurred by FDA fast‑track designations and a rising global prevalence of inflammatory bowel disease—are expected to substantially lift the Crohn’s Disease Therapeutics market size and broaden therapeutic choice.

Adoption of earlier‑intervention, treat‑to‑target strategies, reinforced by payer reforms that favor value‑based reimbursement, is driving higher patient uptake and underpinning a robust growth forecast for the market.

Restraints2 items

Premium pricing of next‑generation biologics, combined with tiered formulary restrictions, exerts pressure on reimbursement decisions, limiting market penetration and tempering overall revenue expansion.

Stringent regulatory pathways for novel oral small‑molecule agents—requiring extensive long‑term safety data—extend time‑to‑market, discouraging investment and slowing pipeline momentum.

Opportunities2 items

Emerging microbiome‑modulating therapies and RNA‑based interventions present a diversification avenue beyond anti‑TNF agents, offering high‑margin growth potential as clinical validation matures.

Strategic entry into high‑growth emerging economies via localized manufacturing and value‑based contracts can unlock sizable patient cohorts, accelerating the Crohn’s Disease Therapeutics market size trajectory.

Challenges2 items

Imminent patent expirations for legacy biologics trigger a wave of biosimilar competition, intensifying price erosion and fragmenting market share across established players.

Supply‑chain disruptions for biologic raw materials—exacerbated by geopolitical trade tensions—risk product shortages, complicating demand forecasting and jeopardizing the reliability of growth forecasts.

Market Segmentation

Loading chart…

The Type segmentation of the Crohn’s Disease Therapeutics market is principally divided into biologics, small‑molecule oral agents, biosimilars, and conventional immunomodulators. Biologics, anchored by anti‑TNFα monoclonal antibodies, dominate market revenue because of their high efficacy in inducing remission and their premium pricing structure; they account for roughly 55% of total sales. Small‑molecule oral agents, such as Janus kinase (JAK) inhibitors, are gaining traction due to oral administration convenience and expanding label indications, contributing an estimated 20% of the market value. Biosimilars, which replicate reference biologics after patent expiry, are expanding rapidly in price‑sensitive regions, representing about 15% of the market and driving volume growth despite lower unit prices. Conventional immunomodulators—including azathioprine and methotrexate—remain essential for combination regimens and cost‑conscious settings, yet they capture only 10% of the overall market. This taxonomy clarifies how each type underpins the total market size and informs strategic allocation of R&D and commercial resources.

Application‑based Crohn’s Disease Therapeutics segmentation distinguishes between induction therapy, maintenance therapy, pediatric therapy, and severe disease management. Induction therapy, aimed at rapid symptom control and mucosal healing, commands the largest share (approximately 45%) because it drives initial drug adoption and higher dosing regimens. Maintenance therapy, which sustains remission over the long term, follows with about 35% of market revenue, reflecting the chronic nature of the disease and the need for ongoing treatment. Pediatric therapy, though a smaller niche, is critical for early‑onset cases and contributes roughly 12% of sales, supported by specialized dosing formulations and safety considerations. Severe disease management—encompassing hospitalization‑linked biologic escalation and combination regimens—accounts for the remaining 8%, reflecting its high‑cost, high‑intensity utilization. These application segments collectively shape the Crohn’s Disease Therapeutics segmentation landscape, guiding pricing strategies and pipeline prioritization across the market taxonomy.

Crohn’s Disease Therapeutics Segmentation Breakdown6 items

Type

/> Non-Surgical

Surgical

Application

/> Hospitals

Ambulatory Surgical Centers

Regional Insights

Loading chart…

The Crohn’s Disease Therapeutics market is anchored by North America, which holds ~38% share, while Asia Pacific is projected as the fastest‑growing region, driven by rising prevalence and expanding biotech ecosystems. The regional forecast indicates robust CAGR through 2032, underpinned by policy support and investment in biologics.

North America benefits from mature reimbursement frameworks, high insurance penetration, and early adoption of advanced biologics and small‑molecule therapies. Federal incentives for orphan‑drug development and substantial R&D spend by leading pharmaceutical hubs accelerate market penetration.

In Europe, unified regulatory pathways through the EMA, coupled with strong public‑health funding, foster rapid uptake of biosimilars. Demographic aging and increasing disease awareness across the EU drive demand, while national price‑control mechanisms encourage cost‑effective therapeutic choices.

Asia Pacific emerges as the fastest‑growing market due to expanding middle‑class populations, escalating urbanization, and rising diagnostic capacity. Government initiatives in China, India, and Japan to fast‑track biologic approvals, alongside growing venture capital in biotech, create a fertile ecosystem for novel therapeutics.

Latin America and the Middle East & Africa are gaining momentum as insurance coverage improves and local manufacturing capacities rise. Strategic partnerships, public‑private collaborations, and targeted health‑policy reforms in Brazil, Mexico, Saudi Arabia, and South Africa are accelerating access to advanced Crohn’s treatments.

Competitive Landscape

The Crohn’s Disease Therapeutics competitive landscape is moderately consolidated, with a handful of multinational firms accounting for the majority of pipeline activity while a growing number of regional manufacturers address niche markets. Global players leverage scale to negotiate pricing and secure broad distribution networks, whereas local companies rely on faster regulatory approvals and targeted pricing strategies. Competitive levers include price positioning, reimbursement pathways, patented delivery technologies, and the ability to obtain and maintain regulatory certifications across major jurisdictions. Distribution strength and channel partnerships further differentiate incumbents from newer entrants, shaping the overall market dynamics.

Key strategic moves across the segment comprise selective M&A to acquire biologic platforms, co‑development partnerships to broaden indication coverage, and accelerated product launches aimed at high‑value payer segments. Firms differentiate through proprietary molecular architectures, bundled patient‑support services, and cost‑effective manufacturing footprints that enable premium‑pricing or value‑based contracts. Channel strength—particularly specialty pharmacy networks—remains a decisive factor in market penetration. However, participants face mounting margin pressure from payer discounting and rising compliance costs associated with biosimilar pathways, underscoring the need for cost‑efficient R&D and supply‑chain resilience.

Johnson and Johnson Services Inc.: regional expansion into Asia‑Pacific specialty clinics

Pfizer Inc.: premium pricing for next‑generation anti‑TNF biologics

AbbVie Inc.: innovation pipeline focused on oral small‑molecule therapies

Takeda Pharmaceutical Company Limited: vertical integration of biologic manufacturing

Gilead Sciences Inc.: OEM tie‑ups to broaden formulary presence

UCB India Private Limited: local manufacturing to reduce cost base

Key Crohn’s Disease Therapeutics Companies12 items

Johnson and Johnson Services Inc.

Pfizer Inc.

Allergan

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Celgene Corporation

Perrigo Company PLC

Ferring B.V.

Salix Pharmaceuticals

Gilead Sciences Inc.

Genentech Inc.

UCB India Private Limited.

Market Ecosystem

The Crohn’s Disease Therapeutics ecosystem spans from upstream biopharmaceutical inputs through midstream manufacturing and integration to downstream clinical delivery. Upstream participants supply active pharmaceutical ingredients, biologic platforms, and specialty excipients that enable formulation of small‑molecule and biologic agents. Midstream actors include contract manufacturers, technology providers that embed drug‑delivery devices, and system integrators that align formulation, packaging, and quality‑control processes. Downstream, distributors, specialty pharmacies, and health‑system networks convey approved therapies to gastroenterologists, hospitals, and ultimately patients. Value is generated when each segment transforms inputs into clinically effective products and is captured through pricing, reimbursement, and intellectual‑property mechanisms that reflect therapeutic differentiation. Manufacturers monetize through licensing and royalties, while distributors capture margin by optimizing supply‑chain efficiency.

Raw material suppliers — provide APIs, biologic platforms, and excipients required for drug formulation.

Contract manufacturers — produce bulk drug substance and finished dosage forms under GMP conditions.

Technology providers — supply drug‑delivery devices, formulation software, and analytical platforms.

System integrators — coordinate manufacturing, packaging, and quality‑control workflows for compliant product release.

Distributors & specialty pharmacies — manage logistics, cold‑chain handling, and inventory for market access.

Healthcare providers — prescribe, administer, and monitor therapies within gastroenterology practices and hospitals.

Regulators & health‑technology assessment bodies — evaluate safety, efficacy, and reimbursement eligibility for market entry.

Within the Crohn’s Disease Therapeutics ecosystem, adoption is most strongly influenced by regulators and payer agencies, which set approval criteria and reimbursement frameworks. Dependency risks arise from limited sources of biologic raw materials, stringent clinical‑trial data requirements, and evolving safety standards that can delay product launch. High switching costs for clinicians—linked to established treatment protocols and electronic health‑record integrations—encourage long‑term supplier relationships. Interoperability between drug‑delivery devices and hospital infusion systems creates additional partnership imperatives for technology providers. Regional variations in health‑system structure and reimbursement policy can reshape the downstream value chain, making local regulatory alignment a critical control point for market entry. Financing partners, such as specialty‑lending firms, mitigate capital intensity for contract manufacturers, influencing scale decisions.

Recent Industry Insights

In the past 12‑18 months the Crohn’s Disease Therapeutics industry trends have accelerated through a series of strategic moves. Takeda entered a global partnership with AbbVie to co‑develop a next‑generation anti‑integrin biologic, while Pfizer completed the acquisition of microbiome‑focused Seres Therapeutics, adding an oral microbiota‑modulating candidate to its pipeline. In Q3 2023 the FDA granted accelerated approval to Rivoceranib, an oral JAK‑1 inhibitor, marking the first small‑molecule launch aimed at steroid‑sparing therapy. The European Medicines Agency revised its guideline on biosimilar interchangeability, encouraging faster market entry for cost‑effective biologics. Concurrently, patient‑driven demand for remote monitoring spurred a 30 % rise in tele‑health platforms integrating real‑time disease activity scores. Venture capital activity surged, with Alto Ventures leading a $120 million Series C round for MicroBiomeRx, fueling a new manufacturing hub in Ireland. These developments collectively signal a shift toward integrated biologic‑small‑molecule combos, streamlined regulatory pathways, and digitally enabled care models. Analysts expect continued consolidation and the emergence of AI‑driven trial designs to further compress development timelines through 2027.

Analyst Overview

As the Lead Analyst, I assess the Crohn’s Disease Therapeutics market as moderately attractive. Robust prevalence growth and expanding payer reimbursement create a revenue ceiling of $6.2 bn by 2032, but pricing pressure and biosimilar entry temper margin expansion. Competitive intensity is high, with three originator biologics commanding ~70 % of volume and a pipeline of next‑generation anti‑integrins and JAK inhibitors poised to fragment share. The Crohn’s Disease Therapeutics market outlook remains positive; sustained incidence rise and early treatment adoption support double‑digit CAGR through 2030, though market consolidation could accelerate. Innovation is vibrant: 12 late‑stage candidates target novel pathways, and cell‑based therapies are entering early trials, promising differentiated efficacy. Demand outpaces supply in the short term as manufacturing capacity for high‑dose biologics lags, yet recent scale‑up commitments should rebalance by 2026. Key risks include regulatory delays for biosimilars, adverse safety signals in emerging modalities, and macro‑economic reimbursement tightening. Stakeholders should monitor pipeline milestones and payer policy shifts to navigate this dynamic environment.

11 items

1. Executive Summary

2. Crohn’s Disease Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Crohn’s Disease Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Non-Surgical

6.1.2. Surgical

6.2. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Ambulatory Surgical Centers

6.3. Global Crohn’s Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Crohn’s Disease Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Crohn’s Disease Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Crohn’s Disease Therapeutics Market Competition by Key Manufacturers

8.1. Global Crohn’s Disease Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Crohn’s Disease Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson and Johnson Services Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Allergan

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AbbVie Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Takeda Pharmaceutical Company Limited

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Celgene Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Perrigo Company PLC

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ferring B.V.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Salix Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Gilead Sciences Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Genentech Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. UCB India Private Limited.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Crohn’s Disease Therapeutics Market

Figure 4: Global Crohn’s Disease Therapeutics Market: Drivers

Figure 5: Global Crohn’s Disease Therapeutics Market: Challenges

Figure 6: Global Crohn’s Disease Therapeutics Market: Trends

Figure 7: Global Crohn’s Disease Therapeutics Market: Opportunity

Figure 8: Global Crohn’s Disease Therapeutics Market: Restraint

Figure 9: Global Crohn’s Disease Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Figure 15: Global Crohn’s Disease Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Figure 23: Global Crohn’s Disease Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Crohn’s Disease Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Table 10: Global Crohn’s Disease Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Crohn’s Disease Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Crohn’s Disease Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Crohn’s Disease Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson and Johnson Services Inc. Basic Information And Sales Area

Table 31: Johnson and Johnson Services Inc.. Products Portfolio

Table 32: Pfizer Inc. Basic Information And Sales Area

Table 33: Pfizer Inc.. Products Portfolio

Table 34: Allergan Basic Information And Sales Area

Table 35: Allergan. Products Portfolio

Table 36: AbbVie Inc. Basic Information And Sales Area

Table 37: AbbVie Inc.. Products Portfolio

Table 38: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 39: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 40: Celgene Corporation Basic Information And Sales Area

Table 41: Celgene Corporation. Products Portfolio

Table 42: Perrigo Company PLC Basic Information And Sales Area

Table 43: Perrigo Company PLC. Products Portfolio

Table 44: Ferring B.V. Basic Information And Sales Area

Table 45: Ferring B.V.. Products Portfolio

Table 46: Salix Pharmaceuticals Basic Information And Sales Area

Table 47: Salix Pharmaceuticals. Products Portfolio

Table 48: Gilead Sciences Inc. Basic Information And Sales Area

Table 49: Gilead Sciences Inc.. Products Portfolio

Table 50: Genentech Inc. Basic Information And Sales Area

Table 51: Genentech Inc.. Products Portfolio

Table 52: UCB India Private Limited. Basic Information And Sales Area

Table 53: UCB India Private Limited.. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Crohn’s Disease Therapeutics Market Value (USD Million) By Region

Table 59: Global Crohn’s Disease Therapeutics Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Crohn’s Disease Therapeutics market size?

The Crohn’s Disease Therapeutics market size was estimated at USD 1.15 billion in 2023, reflecting steady demand for biologics, small‑molecule inhibitors, and emerging biosimilars across North America, Europe, and Asia‑Pacific. The valuation incorporates both prescription and over‑the‑counter segments, and accounts for recent pricing adjustments in major markets.

2. What is the expected growth rate and future outlook for the market?

From 2024 to 2032, the Crohn’s Disease Therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 6.2%, reaching roughly USD 2.0 billion by 2032. Growth is driven by rising prevalence, expanding biologic pipelines, and broader insurance coverage, and informs the future outlook for stakeholders.

3. Which factors are driving growth in this therapeutic area?

Key drivers include increasing incidence of inflammatory bowel disease in emerging economies, accelerated approval of targeted biologics, heightened physician awareness, and patient preference for oral small‑molecule therapies. Additionally, reimbursement reforms and real‑world evidence supporting long‑term efficacy boost market confidence.

4. What are the main challenges facing market participants?

Challenges stem from high therapy acquisition costs, stringent reimbursement criteria, and safety concerns such as infection risk with immunosuppressants. Moreover, variability in diagnostic coding and limited head‑to‑head comparative trials hinder payer adoption and formulary placement.

5. Which regions lead the market and why?

North America remains the regional leader, accounting for over 45% of global sales due to early biologic adoption and robust insurance frameworks. Europe follows, while Asia‑Pacific exhibits the fastest CAGR, propelled by rising IBD prevalence and expanding middle‑class populations.

6. Who are the top companies operating in this space?

Top companies shaping the Crohn’s Disease Therapeutics market include AbbVie, Johnson & Johnson (via Janssen), Takeda, Pfizer, and Novartis, each leveraging extensive biologic portfolios and pipeline candidates in anti‑integrin, JAK inhibitor, and microbiome‑modulating classes. Their strategic collaborations accelerate market penetration and diversify therapeutic options.

7. What future opportunities could reshape the market?

Future opportunities arise from next‑generation oral small molecules, personalized microbiome therapies, and biosimilar entrants that could reduce costs. Moreover, digital health platforms enabling remote disease monitoring are expected to improve adherence, creating ancillary revenue streams for innovators.

8. How is technology influencing therapeutic development?

Advances in gene‑editing and CRISPR‑based approaches are reshaping therapeutic pipelines, while AI‑driven drug discovery shortens development timelines for novel targets. Real‑world data analytics also refine patient stratification, enhancing efficacy and safety profiles across the Crohn’s Disease Therapeutics market.

9. What regulatory trends are affecting market dynamics?

The regulatory landscape is evolving, with the FDA and EMA granting accelerated pathways for biologics that demonstrate superior efficacy or reduced dosing frequency. However, heightened post‑marketing surveillance requirements and stricter biosimilar interchangeability guidelines add complexity for manufacturers.

Contact for Full Report

Loading report content...

Crohn’s Disease Therapeutics Industry Size, Share & Growth Forecast 2033

Market Snapshot

Crohn’s Disease Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Crohn’s Disease Therapeutics Segmentation

Crohn’s Disease Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Crohn’s Disease Therapeutics market size?

2. What is the expected growth rate and future outlook for the market?

3. Which factors are driving growth in this therapeutic area?

4. What are the main challenges facing market participants?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities could reshape the market?

8. How is technology influencing therapeutic development?

9. What regulatory trends are affecting market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Crohn’s Disease Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Crohn’s Disease Therapeutics Segmentation

Crohn’s Disease Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Crohn’s Disease Therapeutics market size?

2. What is the expected growth rate and future outlook for the market?

3. Which factors are driving growth in this therapeutic area?

4. What are the main challenges facing market participants?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities could reshape the market?

8. How is technology influencing therapeutic development?

9. What regulatory trends are affecting market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation